User profiles for Gabriela Patilea-Vrana
Gabriela Patilea-VranaSeattle Genetics Verified email at seagen.com Cited by 628 |
Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and …
Z Zhang, MZ Imperial, GI Patilea-Vrana… - Drug Metabolism and …, 2017 - ASPET
Determining fetal drug exposure (except at the time of birth) is not possible for both logistical
and ethical reasons. Therefore, we developed a novel maternal-fetal physiologically based …
and ethical reasons. Therefore, we developed a novel maternal-fetal physiologically based …
A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics
EJ Cox, N Maharao, G Patilea-Vrana… - Pharmacology & …, 2019 - Elsevier
In the United States, the evolving landscape of state-legal marijuana use for recreational
and/or medical purposes has given rise to flourishing markets for marijuana and derivative …
and/or medical purposes has given rise to flourishing markets for marijuana and derivative …
Drug concentration asymmetry in tissues and plasma for small molecule–related therapeutic modalities
The well accepted “free drug hypothesis” for small-molecule drugs assumes that only the
free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. …
free (unbound) drug concentration at the therapeutic target can elicit a pharmacologic effect. …
Transport vs. metabolism: what determines the pharmacokinetics and pharmacodynamics of drugs? Insights from the extended clearance model
G Patilea‐Vrana, JD Unadkat - Clinical Pharmacology & …, 2016 - Wiley Online Library
The well‐stirred hepatic clearance model (WSHM) has been expanded to include drug
transporters (ie, extended clearance model [ECM]). However, the consequences of this …
transporters (ie, extended clearance model [ECM]). However, the consequences of this …
Characterizing and quantifying extrahepatic metabolism of (−)-Δ9-tetrahydrocannabinol (THC) and its psychoactive metabolite,(±)-11-hydroxy-Δ9-THC (11-OH-THC)
AR Kumar, GI Patilea-Vrana, O Anoshchenko… - Drug metabolism and …, 2022 - ASPET
(−)-Δ 9 -Tetrahydrocannabinol (THC) is the psychoactive constituent of cannabis, a drug
recreationally consumed orally or by inhalation. Physiologically based pharmacokinetic (PBPK) …
recreationally consumed orally or by inhalation. Physiologically based pharmacokinetic (PBPK) …
Development and Verification of a Linked Δ9-THC/11-OH-THC Physiologically Based Pharmacokinetic Model in Healthy, Nonpregnant Population and Extrapolation …
GI Patilea-Vrana, JD Unadkat - Drug Metabolism and Disposition, 2021 - ASPET
Conducting clinical trials to understand the exposure risk/benefit relationship of cannabis
use is not always feasible. Alternatively, physiologically based pharmacokinetic (PBPK) …
use is not always feasible. Alternatively, physiologically based pharmacokinetic (PBPK) …
Hepatic enzymes relevant to the disposition of (−)-∆ 9-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC
GI Patilea-Vrana, O Anoshchenko… - Drug Metabolism and …, 2019 - ASPET
Marijuana use by pregnant women is increasing. To predict developmental risk to the fetus/neonate
from such use, in utero fetal exposure to (−)-∆ 9 -tetrahydrocannabinol (THC), the …
from such use, in utero fetal exposure to (−)-∆ 9 -tetrahydrocannabinol (THC), the …
Quantifying hepatic enzyme kinetics of (-)-∆ 9-Tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling
GI Patilea-Vrana, JD Unadkat - Drug Metabolism and Disposition, 2019 - ASPET
The prevalence of cannabis use and the concentrations of the psychoactive cannabinoid in
cannabis, (-)-∆ 9 -tetrahydrocannabinol (THC), are rising. Physiologically based …
cannabis, (-)-∆ 9 -tetrahydrocannabinol (THC), are rising. Physiologically based …
[HTML][HTML] 731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: Interim results of a …
…, R Sanborn, S Peters, Y Sun, G Patilea-Vrana… - 2022 - jitc.bmj.com
Background Integrin beta-6 plays a role in tumor pathogenesis and invasiveness, and is
correlated with poor outcomes in several cancers, making it a therapeutic target of interest. SGN-…
correlated with poor outcomes in several cancers, making it a therapeutic target of interest. SGN-…
When does the rate-determining step in the hepatic clearance of a drug switch from sinusoidal uptake to all hepatobiliary clearances? Implications for predicting drug …
GI Patilea-Vrana, JD Unadkat - Drug Metabolism and Disposition, 2018 - ASPET
For dual transporter-enzyme substrate drugs, the extended clearance model can be used to
predict the rate-determining step(s) (RDS) of a drug and hence predict its drug-drug …
predict the rate-determining step(s) (RDS) of a drug and hence predict its drug-drug …